Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract

Reshma Mahtani, John S. Macdonald

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Cetuximab is a recently approved monoclonal antibody that targets the epidermal growth factor receptor, a receptor tyrosine kinase involved in the development and progression of colorectal cancer (CRC) and other solid tumors. Cetuximab, as a single agent or in combination with chemotherapy, has demonstrated significant clinical efficacy against CRC. Combinations of cetuximab with chemotherapy have proven to be well tolerated, with minimal overlap of toxicities between agents; and the anticancer synergy between cetuximab and traditional chemotherapy agents has made cetuximab a vital treatment for patients who are no longer responsive to chemotherapy alone. The U.S. Food and Drug Administration approved cetuximab in combination with irinotecan for the treatment of irinotecan-refractory metastatic CRC or as monotherapy for treating patients intolerant to irinotecan. Combination chemotherapies involving cetuximab as well as combinations involving cetuximab and other targeted agents, such as bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, constitute powerful new treatment options for the management of CRC. This review discusses recent clinical studies that have further defined this synergy, focusing primarily on tumors of the gastrointestinal tract.

Original languageEnglish
Pages (from-to)39-50
Number of pages12
JournalOncologist
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

irinotecan
Gastrointestinal Tract
Drug Therapy
Colorectal Neoplasms
Neoplasms
Combination Drug Therapy
Monoclonal Antibodies
Cetuximab
Receptor Protein-Tyrosine Kinases
United States Food and Drug Administration
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Therapeutics

Keywords

  • Cetuximab
  • Chemotherapy
  • Colorectal cancer
  • EGFR

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. / Mahtani, Reshma; Macdonald, John S.

In: Oncologist, Vol. 13, No. 1, 01.01.2008, p. 39-50.

Research output: Contribution to journalArticle

@article{ae1aabc7f2c04de791e11e51e8108a3d,
title = "Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract",
abstract = "Cetuximab is a recently approved monoclonal antibody that targets the epidermal growth factor receptor, a receptor tyrosine kinase involved in the development and progression of colorectal cancer (CRC) and other solid tumors. Cetuximab, as a single agent or in combination with chemotherapy, has demonstrated significant clinical efficacy against CRC. Combinations of cetuximab with chemotherapy have proven to be well tolerated, with minimal overlap of toxicities between agents; and the anticancer synergy between cetuximab and traditional chemotherapy agents has made cetuximab a vital treatment for patients who are no longer responsive to chemotherapy alone. The U.S. Food and Drug Administration approved cetuximab in combination with irinotecan for the treatment of irinotecan-refractory metastatic CRC or as monotherapy for treating patients intolerant to irinotecan. Combination chemotherapies involving cetuximab as well as combinations involving cetuximab and other targeted agents, such as bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, constitute powerful new treatment options for the management of CRC. This review discusses recent clinical studies that have further defined this synergy, focusing primarily on tumors of the gastrointestinal tract.",
keywords = "Cetuximab, Chemotherapy, Colorectal cancer, EGFR",
author = "Reshma Mahtani and Macdonald, {John S.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2006-0049",
language = "English",
volume = "13",
pages = "39--50",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract

AU - Mahtani, Reshma

AU - Macdonald, John S.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Cetuximab is a recently approved monoclonal antibody that targets the epidermal growth factor receptor, a receptor tyrosine kinase involved in the development and progression of colorectal cancer (CRC) and other solid tumors. Cetuximab, as a single agent or in combination with chemotherapy, has demonstrated significant clinical efficacy against CRC. Combinations of cetuximab with chemotherapy have proven to be well tolerated, with minimal overlap of toxicities between agents; and the anticancer synergy between cetuximab and traditional chemotherapy agents has made cetuximab a vital treatment for patients who are no longer responsive to chemotherapy alone. The U.S. Food and Drug Administration approved cetuximab in combination with irinotecan for the treatment of irinotecan-refractory metastatic CRC or as monotherapy for treating patients intolerant to irinotecan. Combination chemotherapies involving cetuximab as well as combinations involving cetuximab and other targeted agents, such as bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, constitute powerful new treatment options for the management of CRC. This review discusses recent clinical studies that have further defined this synergy, focusing primarily on tumors of the gastrointestinal tract.

AB - Cetuximab is a recently approved monoclonal antibody that targets the epidermal growth factor receptor, a receptor tyrosine kinase involved in the development and progression of colorectal cancer (CRC) and other solid tumors. Cetuximab, as a single agent or in combination with chemotherapy, has demonstrated significant clinical efficacy against CRC. Combinations of cetuximab with chemotherapy have proven to be well tolerated, with minimal overlap of toxicities between agents; and the anticancer synergy between cetuximab and traditional chemotherapy agents has made cetuximab a vital treatment for patients who are no longer responsive to chemotherapy alone. The U.S. Food and Drug Administration approved cetuximab in combination with irinotecan for the treatment of irinotecan-refractory metastatic CRC or as monotherapy for treating patients intolerant to irinotecan. Combination chemotherapies involving cetuximab as well as combinations involving cetuximab and other targeted agents, such as bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, constitute powerful new treatment options for the management of CRC. This review discusses recent clinical studies that have further defined this synergy, focusing primarily on tumors of the gastrointestinal tract.

KW - Cetuximab

KW - Chemotherapy

KW - Colorectal cancer

KW - EGFR

UR - http://www.scopus.com/inward/record.url?scp=38849142020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849142020&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2006-0049

DO - 10.1634/theoncologist.2006-0049

M3 - Article

C2 - 18245011

AN - SCOPUS:38849142020

VL - 13

SP - 39

EP - 50

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -